Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development

 
• By Emily Hayes
  
Business decline
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D